Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Systematic Radioiodine Administration Versus Guided Decision in Intermediate-risk Differentiated Thyroid Cancer
NCT04290663Phase 3Recruiting
- Sponsor
- Centre François Baclesse
- Start
- Mar 2020
- Primary completion
- Feb 2031
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of iodine-131 in thyroid cancer, sponsored by Centre François Baclesse. Started Mar 2020; status: recruiting.
02
Drugs
iodine-131
03
Conditions
thyroid cancer
Beyond the preview
Go deeper on NCT04290663.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04290663.